Clinical trials: Resectable Lung Non-Small Cell Carcinoma
Squamous Cell Lung Cancer
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001
This will be a single-arm study to primarily evaluate the feasibility of administering necitumumab added to gemcitabine and cisplatin as neoadjuvant treatment in treatment-naïve patients with stage IB (tumor size >4cm), II or…
- Trial name
- NCT03574818
- Testing
- Necitumumab-Gemcitabine-Cisplatin, Evaluation to determine if patient is a candidate to proceeed with surgical resection or not
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Lung Cancer
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
This study will evaluate the efficacy and safety of chemotherapy given prior to having lung cancer surgically removed. Patients with resectable non-small cell lung cancer will receive gemcitabine and pemetrexed together for 4…
- Trial name
- NCT00226577
- Testing
- Gemcitabine, Pemetrexed, Surgery
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
NSCLC, Non Small Cell Lung Cancer
Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT06552000
- Testing
- NovoTTF-200T System
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Non-small Cell Lung Cancer
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.
This study is single arm, open label, phase II trial for resectable ALK+ NSCLC. Eligible patients will receive brigatinib after 7-day lead-in 90mg from 4 to 10 weeks. The objective of this study is as follows.
- Trial name
- NCT05361564
- Testing
- Brigatinib
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Yonsei University
Non Small Cell Lung Cancer
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients…
- Trial name
- NCT05742607
- Testing
- IPH5201 + durvalumab + standard chemotherapy
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- Innate Pharma
Resectable Non-small Lung Cancer
Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer
With the recent approval of Nivolumab for second-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors are entering the standard of care for lung cancer.
- Trial name
- LYMPHOLUNG (NCT02551211)
- Testing
- blood drawn, surgical resection of cancer
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Rouen
Lung Cancer
Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00025389
- Testing
- bevacizumab, carboplatin, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Chicago
Non-small Cell Lung Cancer
Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC
The purpose of this study was to evaluate the safety and efficacy of neoadjuvant concurrent chemoradiation with weekly docetaxel/cisplatin in patients with resectable IIIA-N2 NSCLC.
- Trial name
- NCT01771289
- Testing
- docetaxel/cisplatin, Radiation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Lung Cancer - Non Small Cell
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC).
- Trial name
- GALAXY 3 (NCT06926790)
- Testing
- Nivolumab & Ipilimumab
- Where
- China
- Volunteers
- 69 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607.
- Conditions
- NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection, Overall Lung Function is Adequate for the Planned Lung Resection, AJCC is Classified as IIA-IIIB
- Trial name
- NCT07534033
- Testing
- Probiotics combined with neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhujiang Hospital
Carcinoma, Non-Small-Cell Lung
CIETAI and Sequential Radiotherapy in Squamous Lung Cancer
Central-type lung cancer refers to lung malignancies originating from the segmental bronchi and above. The most common tissue type is squamous cell carcinoma.
- Trial name
- NCT05892237
- Testing
- bronchial artery interventional therapy, Chemotherapy drug, IMRT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Dong Wang
Non Small Cell Lung Cancer
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response.
- Trial name
- TroFuse-019 (NCT06312137)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Cisplatin
- Where
- 270 sites in United States, Argentina and 29 more
- Volunteers
- 780 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC, Stage IIIA
Metabolomics Predict Therapy Response
Complete resection is the mainstay of treatment for stage I-IIIA resectable non-small cell lung cancer (NSCLC). However rates of recurrence of disease are high, with five-year survival rates ranging between 73% (stage IA) and 24%…
- Trial name
- PROLUNG (NCT03736993)
- Testing
- Additional blood sampling
- Where
- 4 sites in Belgium
- Volunteers
- 160 people
- Sponsor
- Hasselt University
Non-Small-Cell-Lung Cancer
Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC
The aim of this study is to evaluate whether by combining a carboplatin-gemcitabine based induction chemotherapy with weekly cisplatin during standard thoracic radiotherapy it is possible to obtain optimal efficacy with minimal…
- Trial name
- CHER@NOS (NCT00463515)
- Testing
- carboplatin/gemcitabine, cisplatin/radiation therapy
- Where
- 3 sites in Belgium
- Volunteers
- 77 people
- Sponsor
- University Hospital, Antwerp
Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
This is an observational, prospective, multicentre and nationwide study. The study enroll resectable stage IIIA non-small cell lung cancer patients that are going to receive neoadjuvant treatment in real world.
- Trial name
- REAL-NADIM (NCT05382052)
- Where
- 20 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Fundación GECP
NSCLC, EGFR Positive Non-small Cell Lung Cancer
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma.
- Conditions
- NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy
- Trial name
- NCT07622706
- Testing
- Firmonertinib 80mg qd oral for 8 weeks., Firmonertinib 160mg qd oral for 8 weeks., Firmonertinib 80mg qd oral for 16 weeks.
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non-small Cell Lung Cancer
Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3
Randomised trial of chemotherapy or not before surgery in early resectable stages of NSCLC (IB, IIA, IIB, and IIIA/N2).
- Trial name
- NCT00273507
- Testing
- Carboplatin and Paclitaxel
- Where
- Denmark
- Volunteers
- 270 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Non-small Cell Lung Cancer
Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer
By exploring the feasibility, effectiveness and safety of neoadjuvant therapy with Sintilimab combined with platinum-containing chemotherapy in patients with resectable Stage ⅡB-ⅢA NSCLC, we will provide new treatment options and…
- Trial name
- NCT05170581
- Testing
- Sintilimab Combined with Platinum-containing Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer
- Trial name
- NCT05500092
- Testing
- Nivolumab, (8gy x 3), Platinum Doublet
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Montefiore Medical Center
Lung Cancer (NSCLC)
Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations
This study evaluates the effectiveness and safety of targeted therapy given before and after surgery in patients with resectable or potentially resectable stage III non-small cell lung cancer with selected genetic alterations.
- Trial name
- NCT07829744
- Testing
- Surgical Resection
- Volunteers
- 190 people
- Sponsor
- Shanghai Zhongshan Hospital